January 30, 2023 at 1:09 pm

Quince Therapeutics Sells Legacy Portfolio to Lighthouse Pharmaceuticals

Biopharmaceutical company, Quince Therapeutics (Nasdaq: QNCX), has sold its legacy small molecule protease inhibitor portfolio to Lighthouse Pharmaceuticals. As a result of the sale, Quince expects to benefit from the reduction of more than $500,000 of annualized expenses associated with the operational and financial support of the assets.  Highlights  Quince may receive up to $150… [Read More]
January 25, 2023 at 10:57 pm

Precigen (PGEN) Falls 25% Upon Announcing $75M Public Offering

Precigen (PGEN) a clinical biopharmaceutical company, fell 25% today, upon announcing a $75M public offering at a share price of $1.75 per share. The Company has also granted the underwriters a 30-day option to purchase up to an additional 6,428,571 shares of its common stock. The Company plans to use the proceeds to fund the… [Read More]
January 25, 2023 at 9:54 am

Lipella Reports Successful Top Line Results in Phase 2a Study

Clinical-stage biotechnology company, Lipella Pharmaceuticals (LIPO) has released positive top line results from its Phase 2a clinical trial investigating a potential treatment for hemorrhagic cystitis. The trial showed statistically significant safety and efficacy for Lipella’s drug candidate, LP-10. The company plans to communicate with the FDA on the study’s results and the pathway forward to… [Read More]
January 23, 2023 at 9:18 pm

Electric Vehicles Stock Jump; EVGO Up 17%

In a positive day for electric vehicles stocks, EVgo (EVGO) jumped over 17%. EVGO leads the PRISM EV Index in performance, helping push the index up 4.2%. EVGO is not the only EV stock that had a great day. Lucid grew 13%, Rivian 12%, NIO 9.3% and Tesla 7.7%. The rise in values among these… [Read More]
January 23, 2023 at 3:59 pm

Former GW Pharmaceuticals President Joins Lexaria

 Lexaria Bioscience (Nasdaq:LEXX) has appointed the former President of GW Pharmaceuticals USA, Julian Gangolli, as a Strategic Advisor. Mr. Gangolli said: “The potential of Lexaria’s disruptive drug delivery technology is significant and I hope to assist Lexaria in its commercial development of DehydraTECH for multiple applications.” Highlights Prior to being acquired by Jazz Pharmaceuticals, GW… [Read More]
January 20, 2023 at 9:01 pm

Biolase (BIOL) Rises 14% After Announcing Positive Momentum and Q4 Revenue Growth

Biolates (BIOL) a leader in dental lasers, jumped 14% for the day, after the Company announced positive momentum through the end of 2022 and signficant market opportunity. Q4 2022 revenue is expected to be around $14 million, above Q4 2021 revenue of $12.4 million. Additional highlights from 2022 are below: Full-year 2022 revenue is expected… [Read More]
January 20, 2023 at 12:36 am

CV Sciences (CVSI) Rises 15% As Company Launches new PlusCBD Softgels

CV Sciences (CVSI), a consumer wellness company specializing in hemp extracts and other proven natural ingredients, jumped 15% for the day shortly after announcing the launch of a new product. The Company’s new offering – +PlusCBD™ Reserve Collection Softgels in a 30-count bottle – will be available on their website on Thursday, Jan. 19. “Consumers… [Read More]
January 19, 2023 at 3:13 pm

Spruce Biosciences Enters Strategic Partnership to Deliver Tildacerfont to Japanese Market

Late-stage biopharmaceutical company, Spruce Biosciences (Nasdaq: SPRB), has announced an exclusive licensing agreement with Kaken Pharmaceuticals to develop and commercialize tildacerfont for congenital adrenal hyperplasia (CAH) in Japan. (CAH) is a genetic disorder in which the two adrenal glands (located at the top of the kidneys) do not function properly. The Company estimates the total… [Read More]
January 18, 2023 at 11:45 pm

Acrimoto, Inc. (FUV) Plunges 59% as Company Announces $12M Equity Offering

Acrimoto, Inc. (FUV), makers of electric vehicles, plunged 59% as the Company announced a public equity offering of $12M. The shares can be purchased at a price of $3.00 per share with an accompanying warrant. The price represents a 50.9% discount on last close of January 17, 2023 and is expected to close January 20,… [Read More]
January 17, 2023 at 9:43 pm

Celyad Oncology (CYAD) Surges 138% and Reaches Five-Month High

Celyad Oncology (CYAD), an oncology biotech company, surged 138% for the day, reaching a new five-month high. It is unclear why the Company soared today, as there were no news on or for the company. The Company’s latest press release is from around a month ago, when they announced a strategic shift to their preclinical… [Read More]
January 17, 2023 at 2:02 pm

As Investors Continue to Gain Interest in the Emerging Name Image and Likeness (NIL) Industry, OpenLocker Steps onto the Court as an Early-Mover in Digital Sports Collectables

The Player: OpenLocker Holdings, Inc. (OTCQB:OLKR)  OpenLocker Holdings is a technology platform for athletes and brands to redefine and unlock consumer and fan value. OpenLocker builds highly engaged fan communities on the Blockchain primarily for colleges and universities using student-athletes Name, Image and Likeness (N.I.L.) opening the door to countless revenue opportunities that previously did… [Read More]
January 17, 2023 at 9:46 am

FDA Clearance Granted to Orchard Therapeutics

FDA Clearance Granted to Orchard Therapeutics Global gene therapy leader, Orchard Therapeutics (Nasdaq: ORTX), has received FDA clearance for its Investigational New Drug application for a hematopoietic stem cell (HSC) gene therapy. OTL-203 is being developed for the treatment of the Hurler subtype of mucopolysaccharidosis type I (MPS-IH). Highlights Orchard’s proof-of-concept trial demonstrated that treatment… [Read More]